The impact of the prevalence of glutathione S-transferase polymorphism on the response of Egyptian CML patients to tyrosine kinase inhibitor (imatinib) /
Amr Mohammed Abd El Fattah,
The impact of the prevalence of glutathione S-transferase polymorphism on the response of Egyptian CML patients to tyrosine kinase inhibitor (imatinib) / تأثير انتشار الجلوتاثيون S- ترانسفيراز تعدد الأشكال علي الإستجابة من المرضي المصريين المصابين بسرطان الدم النخاعى المزمن الى الخط الأول من مثبطات التيروزين كيناز(ايماتينيب) / By Amr Mohammed Abd El Fattah; Under Supervision of Prof. Dr. Nehad Mohammed Tawfeek, Dr. Mohamed Ahmed Fateen, Dr. Ibrahim Ahmed Ibrahim Abdalgawad / - 84 pages : illustrations ; 25 cm. + CD.
Thesis (Ph.D)-Cairo University, 2024.
Bibliography: pages 79-84.
Rationale: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm
with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately
15% of newly diagnosed cases of leukemia in adults. Tyrosine kinase inhibitors
(TKIs) had significantly changed the treatment landscape, improving outcomes
for patients with CML treatment. First generation TKIs imatinib had improved
the 8-years overall survival rate from 20 to 87%. Four generations of TKIs were
approved and commonly used for the treatment of CML. The occurrence of
CML is controlled by a set of factors such as exposure to environmental
carcinogens and the ability to eliminate toxic substances. Resistance to tyrosine
kinase inhibitors constitutes a big challenge in the treatment of patients with
CML. This resistance could be linked to glutathione transferase activity.
Several studies in literature studied the impact of glutathione over CML patients
as risk of both susceptibility, treatment resistance and poor response.
Purpose: This study aims to evaluate the presence of Glutathione transferase
polymorphism on CML patients and the impact of glutathione s polymorphism
on the molecular response BCR-ABL (IS %) on CML patients on the first line
tyrosine kinase inhibitor (imatinib)
Methodology: The study included 50 patients with chronic myeloid leukemia
receiving tyrosine kinase inhibitor imatinib were recruited from outpatient
hematology clinic at kasr El Einy hospital and followed over the period from
October 2021 to October 2023. The patients were investigated for routine
laboratory investigations including complete blood picture, liver functions,
renal functions, molecular BCR-ABL (IS %) and glutathione s polymorphism
Results: The study results show correlation between molecular response BCR-
ABL (IS %) of different groups of the study and severity of anemic
manifestations with statistically significant difference of p value 0.023. The
results of the study show no correlation between Glutathione S polymorphism
and molecular response of CML cases among study group as no statistically
significance difference with p value 0.94 so the study shows no impact of the
GSP1 on the molecular response of the patients تهدف دراستنا إلى تقييم انتشار و تأثير تعدد أشكال الجلوتاثيون على الاستجابة الجزيئية لدى المرضى المصريين بسرطان الدم الميلودي المزمن للجيل لأول من مثبطات التيروزين كيناز (ايماتينيب).
وجدت الدراسة وجود علاقة ذات دلالة إحصائية بين الاستجابة الجزيئية و حدة أعراض فقر الدم بين المجموعات المختلفة حيث وجدنا تحسن في أعراض فقر الدم مع تحسن الاستجابة الجزيئية مع عدم وجود تأثير لتعدد أشكال الجلوتاثيون S على الاستجابة الجزيئية في حالات سرطان الدم النخاعي المزمن على إيماتينيب
Text in English and abstract in Arabic & English.
Leukemia
CML (Chronic myeloid leukemia) Imatinib resistance TKIs (Tyrosine kinase inhibitor ) GSTs (Glutathione transferases)
616.99419
The impact of the prevalence of glutathione S-transferase polymorphism on the response of Egyptian CML patients to tyrosine kinase inhibitor (imatinib) / تأثير انتشار الجلوتاثيون S- ترانسفيراز تعدد الأشكال علي الإستجابة من المرضي المصريين المصابين بسرطان الدم النخاعى المزمن الى الخط الأول من مثبطات التيروزين كيناز(ايماتينيب) / By Amr Mohammed Abd El Fattah; Under Supervision of Prof. Dr. Nehad Mohammed Tawfeek, Dr. Mohamed Ahmed Fateen, Dr. Ibrahim Ahmed Ibrahim Abdalgawad / - 84 pages : illustrations ; 25 cm. + CD.
Thesis (Ph.D)-Cairo University, 2024.
Bibliography: pages 79-84.
Rationale: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm
with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately
15% of newly diagnosed cases of leukemia in adults. Tyrosine kinase inhibitors
(TKIs) had significantly changed the treatment landscape, improving outcomes
for patients with CML treatment. First generation TKIs imatinib had improved
the 8-years overall survival rate from 20 to 87%. Four generations of TKIs were
approved and commonly used for the treatment of CML. The occurrence of
CML is controlled by a set of factors such as exposure to environmental
carcinogens and the ability to eliminate toxic substances. Resistance to tyrosine
kinase inhibitors constitutes a big challenge in the treatment of patients with
CML. This resistance could be linked to glutathione transferase activity.
Several studies in literature studied the impact of glutathione over CML patients
as risk of both susceptibility, treatment resistance and poor response.
Purpose: This study aims to evaluate the presence of Glutathione transferase
polymorphism on CML patients and the impact of glutathione s polymorphism
on the molecular response BCR-ABL (IS %) on CML patients on the first line
tyrosine kinase inhibitor (imatinib)
Methodology: The study included 50 patients with chronic myeloid leukemia
receiving tyrosine kinase inhibitor imatinib were recruited from outpatient
hematology clinic at kasr El Einy hospital and followed over the period from
October 2021 to October 2023. The patients were investigated for routine
laboratory investigations including complete blood picture, liver functions,
renal functions, molecular BCR-ABL (IS %) and glutathione s polymorphism
Results: The study results show correlation between molecular response BCR-
ABL (IS %) of different groups of the study and severity of anemic
manifestations with statistically significant difference of p value 0.023. The
results of the study show no correlation between Glutathione S polymorphism
and molecular response of CML cases among study group as no statistically
significance difference with p value 0.94 so the study shows no impact of the
GSP1 on the molecular response of the patients تهدف دراستنا إلى تقييم انتشار و تأثير تعدد أشكال الجلوتاثيون على الاستجابة الجزيئية لدى المرضى المصريين بسرطان الدم الميلودي المزمن للجيل لأول من مثبطات التيروزين كيناز (ايماتينيب).
وجدت الدراسة وجود علاقة ذات دلالة إحصائية بين الاستجابة الجزيئية و حدة أعراض فقر الدم بين المجموعات المختلفة حيث وجدنا تحسن في أعراض فقر الدم مع تحسن الاستجابة الجزيئية مع عدم وجود تأثير لتعدد أشكال الجلوتاثيون S على الاستجابة الجزيئية في حالات سرطان الدم النخاعي المزمن على إيماتينيب
Text in English and abstract in Arabic & English.
Leukemia
CML (Chronic myeloid leukemia) Imatinib resistance TKIs (Tyrosine kinase inhibitor ) GSTs (Glutathione transferases)
616.99419